Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sulzer Medica

This article was originally published in The Gray Sheet

Executive Summary

Orthopedic and cardiovascular firm's spin-off from parent Sulzer AG completed July 10 following shareholder approval July 9, despite uncertainties over uninsured costs of the recall of its Inter-Op hip shells and related lawsuits (1"The Gray Sheet" June 4, 2001, In Brief)

You may also be interested in...

Sulzer Medica

Spin-off of medical device unit from parent Sulzer Ltd. is slated for July 10 following shareholder meeting on July 9. Following spin-off, the parent will retain a 4% stake in firm. Sulzer management first announced its spinout plan March 9 on the heels of a hostile takeover bid from investor group InCentive Capital. The bid has since failed (1"The Gray Sheet" March 12, 2001, p. 27). Firm also announces appointment of Stephen Rietiker as CEO of the Medica unit, effective August 1. Rietiker, formerly VP and general manager of Covance, replaces current CEO Andre Buchel, who will retire

QUOTED. 3 April 2020. Minetta Liu.

Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts